Health Condition 1: F209- Schizophrenia, unspecified
Conditions
Interventions
Intervention1: Pharmacogenomic based dosing of Aripiprazole: The dose will modified for the patients with genetic polymorphism of CYP2D6, DRD2,5HT2RA
Control Intervention1: Control aripiprazole arm: N
Sponsors
AJIITH XAVIER F
Eligibility
Inclusion criteria
Inclusion criteria: 1.Schizophrenia patients who will be started on aripiprazole therapy 2.Patients >16 years of either gender 3.Patient or legally authorized representative willing to give informed consent
Exclusion criteria
Exclusion criteria: 1.Patients with chronic liver or kidney disease 2.Pregnant and lactating females 3. History of neurological, neuroendocrine, or other medical conditions known to affect the central nervous system. 4. Any significant medical condition that has clinically significant interaction with aripiprazole
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse Effect & therapeutic outcomes with aripiprazole therapeutic regimen based on pharmacogenomic profilingTimepoint: one & three months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.The cost-benefit & conceptual model for personalized medicine and therapeutic OPD for aripiprazole 2.Proposed dose based on genetic polymorphism for CYP3A4, DRD2 and 5HTR2A Timepoint: one & three months | — |
Countries
India
Contacts
Public ContactDRSYED SHARIQ NAEEM
Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim University. Aligarh
Outcome results
None listed